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Background: Fecal calprotectin (FC) has been proposed
as a marker of inflammatory bowel disease (IBD), but
few studies have evaluated its usefulness in patients
with chronic diarrhea of various causes. We evaluated
the diagnostic accuracy of a FC assay in identifying
“organic” causes of chronic diarrhea in consecutive
adults and children.
Methods: We consecutively enrolled 70 adult patients
(30 males, 40 females; median age, 35 years) and 50
children (20 males, 30 females; median age, 3.5 years)
with chronic diarrhea of unknown origin. All patients
underwent a complete work-up to identify the causes of
chronic diarrhea. FC was measured by ELISA.
Results: In adult patients, FC showed 64% sensitivity
and 80% specificity with 70% positive and 74% negative
predictive values for organic causes. False-positive re-
sults (8 of 40 cases) were associated with the use of
aspirin (3 cases) or nonsteroidal antiinflammatory drugs
(1 case) and with the presence of concomitant liver
cirrhosis (3 cases). False-negative results mainly in-
cluded patients suffering from celiac disease (5 cases).
Patients with IBD (9 cases) were identified with 100%
sensitivity and 95% specificity. In pediatric patients,
sensitivity was 70%, specificity was 93%, and positive
and negative predictive values were 96% and 56%.
False-negative results (11 of 35 cases) were associated
mainly with celiac disease (6 cases) or intestinal giardi-
asis (2 cases).
Conclusions: FC assay is an accurate marker of IBD in
both children and adult patients. In adults, false nega-
tives occur (e.g., in celiac disease) and false-positive
results are seen in cirrhosis or users of nonsteroidal
antiinflammatory drugs. Diagnostic accuracy is higher
in children.
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Irritable bowel syndrome (IBS)5 is one the most frequent
causes of chronic diarrhea in adult patients, and previous
studies have suggested that a careful standard medical
history could suggest IBS diagnosis rather than an organic
disease (1, 2). However, the diagnostic work-up of pa-
tients with diarrhea and suspected IBS includes a barium
x-ray study of the colon or sigmoidoscopy, and colonos-
copy is recommended for patients over the age of 50 (3 ).
Consequently, to avoid invasive investigations, several
noninvasive markers have been suggested to distinguish
functional gastrointestinal disorders from “organic” dis-
eases. Among these, fecal calprotectin (FC) concentrations
have been shown to be a good marker of organic disease,
being higher in patients with inflammatory bowel disease
(IBD) (4 ) and colorectal carcinoma than in controls (5 ).
Calprotectin constitutes 60% of the soluble cytosol pro-
teins in neutrophil granulocytes and plays a central role in
neutrophil defense. Consequently, its concentration in
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stool correlates with the intensity of neutrophil infiltration
of the intestinal mucosa and with the severity of inflam-
mation. Furthermore, its in vivo and in vitro resistance to
degradation allows fecal samples to be assayed for a
reliable calprotectin determination (6 ). Most previous
studies on the FC assay, however, were carried out on
prediagnosed groups of patients, and its diagnostic accu-
racy in distinguishing organic from “functional” diarrhea
has rarely been evaluated in adult patients (4, 7, 8) and
never in children.
The aim of the present study was to evaluate the
positive and negative predictive values of the FC assay in
identifying the organic causes of chronic diarrhea in
consecutive individuals referred as outpatients to gastro-
enterology centers both for adults and for children.
Patients and Methods
We enrolled all consecutive patients referred for chronic
diarrhea to the outpatient clinics of the Division of Inter-
nal Medicine of the University Hospital and of the Pedi-
atric Division of “Di Cristina” Hospital, both in Palermo,
between January and June 2001. Thirty-eight individuals
during the same period were recruited as controls; they
were apparently healthy or were prediagnosed as having
IBD.
study design
The inclusion criterion was a history of chronic diarrhea
of unknown origin, lasting for more than 4 weeks, with or
without abdominal pain. Exclusion criteria included pre-
vious evaluation for chronic diarrhea, overt gastrointesti-
nal bleeding, sigmoidoscopy or colonoscopy during the
previous 2 years performed for any cause, familial adeno-
matous polyposis and hereditary nonpolyposis, colorectal
cancer syndrome, and pregnancy.
For each participant in the study, data were collected
about the use of nonsteroidal antiinflammatory drugs
(NSAIDs), aspirin, and anticoagulants. The concomitant
presence of other nongastroenterologic diseases, in par-
ticular, rheumatoid arthritis or other connective tissue
inflammatory diseases, or respiratory or urinary tract
inflammation/infection, was recorded to evaluate a pos-
sible influence of these diseases on FC concentration.
A full medical history was obtained from all adults
enrolled in the study, and a physical examination was
performed; each patient was evaluated by documentation
of the Rome criteria, which are considered a guide for IBS
diagnosis (9 ). In addition, all patients underwent first-
step hematology and chemistry tests (including erythro-
cyte sedimentation rate, serum C-reactive protein, blood
cell counts, electrolytes, and thyroid, liver, and renal
function); serologic assays for suspected celiac disease
(anti-gliadin IgA and IgG and anti-transglutaminase IgA);
stool examination for occult blood, ova, and parasites; and
a lactose-H2 breath test. In accordance with the current
diagnostic approach (3, 10), adult patients also under-
went sigmoidoscopy with biopsy if under 40 years of age
or colonoscopy with biopsy if over 40. Patients with
negative results for all of the examinations described
above and with a clinical history indicative of IBS accord-
ing to the Manning criteria (1 ) were considered to be
suffering from IBS and began a therapeutic trial with
amitriptyline or propantheline bromide plus bromaz-
epam.
Pediatric patients underwent the same first-step exam-
inations as the adults with the exception of the lactose-H2
breath test, but particular attention was given to a possi-
ble diagnosis of cow’s milk intolerance/allergy. This
included an elimination diet without cow’s milk and its
derivatives, and the patients cured or improved on this
diet underwent a subsequent double-blind cow’s milk
challenge as described previously (11 ). The disappear-
ance of the diarrhea on elimination diet and its reappear-
ance on food challenge was considered indicative of food
intolerance. In addition, children with positive occult
blood in the stool or with serum indices of inflammation
(positive serum C-reactive protein, erythrocyte sedimen-
tation rate 20, increased white blood cell or platelet
count) underwent colonoscopy with biopsy. Pediatric
patients negative for all the first-step examinations were
considered to be suffering from IBS and began a thera-
peutic trial with trimebutine.
All participants with one or more positive examina-
tions at the first-step evaluation, according to the judg-
ment of the individual laboratory/instrumental data phy-
sicians, underwent a diagnostic work-up, which may
have included esophago-gastro-duodenoscopy, colonos-
copy, small intestine barium examination, abdominal
ultrasonography, and/or computed tomography scan,
transit test, and duodenal fluid microbiological evalua-
tion.
Subsequent monthly follow-up for 17–23 months (me-
dian, 20 months) was performed to confirm the initial
diagnoses. In particular, a diagnosis of IBS was confirmed
if diarrhea disappeared or improved during treatment
and when routine hematochemical analyses, evaluated
every 6 months, remained within reference values. Other
diseases were diagnosed using generally accepted con-
ventional criteria.
For the adult patients, two control groups were se-
lected: one composed of 10 patients suffering from active
ileocolonic Crohn disease (5 males, 5 females; age range,
20–65 years; median, 35 years), diagnosed according to
standard endoscopy and histology criteria, and the other
composed of 10 healthy volunteers (5 males and 5 fe-
males; age range, 25–45 years; median, 30 years). Among
the patients suffering from Crohn disease, four had an
exclusive ileum localization, five an ileum-colon localiza-
tion, and one an exclusive colon localization. Eight of
these patients were studied during an acute phase of the
disease, and the median Crohn Disease Activity Index
(12 ) in these patients was 195 (range, 60–300; values150
indicate nonactive disease).
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Similarly, two control groups were enrolled for the
pediatric patients: the first composed of 8 patients suffer-
ing from ileocolonic Crohn disease (5 males, 3 females;
age range, 4–12 years; median, 10 years), diagnosed
according to standard endoscopy and histology criteria;
the second composed of 10 healthy children (5 males, 5
females; age range, 1–10 years; median, 3.5 years). The
pediatric patients included in the Crohn disease control
group were in an active phase of the disease, and all had
an ileum-colon localization. The severity of their disease
was assessed by the Lloyd–Still score (13 ), which ranged
between 25 and 61 (values 75 indicate nonactive dis-
ease).
The protocol was approved by the ethics committee of
the University Hospital of Palermo, and informed consent
was obtained from the adult patients and the parents of
the children involved in the study.
fc assay
One stool sample for calprotectin estimation was collected
and returned by each study participant within 1 week of
the first visit. Laboratory personnel unaware of the clini-
cal diagnoses or details of the patients’ clinical histories
stored the specimens at 20 °C and assayed calprotectin
within 4 weeks. After thawing, calprotectin concentra-
tions were measured by a commercial ELISA system
(Calprest; Eurospital) based on polyclonal antibodies
against calprotectin, according to the method modified by
Ton et al. (14 ). Two 100-mg fecal aliquots from a single
stool sample from each participant were assayed, and the
mean of the two measurements was recorded. Threshold
values supplied by the manufacturer (50 g/g of
stool negative; 50–100 g/g of stool borderline;100
g/g of stool  positive) were considered for statistical
analysis. The intraassay CV for FC was 3.1% at a mean
(SD) of 63 (20) g/g (n  25), and the interassay CV was
10% at 76 (21) g/g (n  25).
The gastroenterologists who made the final diagnoses
were unaware of the FC results throughout the study.
statistical analysis
We followed the STARD checklist for studies on the
diagnostic accuracy of tests (15 ).
The sensitivity and specificity of the FC assay and its
positive and negative predictive values, along with their
95% confidence intervals, were calculated by standard
statistical methods (16 ). The Mann–Whitney test was
used to compare the FC values recorded in IBS patients
and in the other groups studied. The Fisher exact test was
used to compare the frequency of the association between
false-positive results and drug use or presence of other
associated diseases. The Pearson correlation coefficient
was calculated to verify the correlation between individ-
ual FC concentration and the activity index of the Crohn
disease.
Results
A total of 126 consecutive patients with chronic diarrhea
were initially included in the study. Six patients (four
adults and two children), all diagnosed as suffering from
IBS after the first clinical/laboratory evaluation, were lost
during the follow-up; consequently, their data were ex-
cluded from the final analysis. Thus a total of 70 adult
patients (30 males, 40 females; age range, 18–72 years;
median, 35 years) and 50 children (20 males, 30 females;
age range, 8 months–10 years; median, 3.5 years) were
enrolled.
The final diagnoses for the 120 patients with chronic
diarrhea who completed the study, divided into adults
and children, are shown in Table 1. None had more than
one gastrointestinal disease. The final diagnosis was IBS
in 55 patients (40 adults and 15 children), whereas in the
other 65 patients (30 adults and 35 children), an organic
cause of chronic diarrhea was found. In all cases, the
clinical and laboratory follow-up confirmed these diag-
noses.
The median and ranges of FC concentrations in pa-
tients with IBS, in patients with organic chronic diarrhea,
and in the control groups are shown in Table 2. In adult
patients, individuals with an organic cause of diarrhea
had significantly higher FC concentrations than individ-
uals with IBS (P  0.03, Mann–Whitney test). The values
of the age-matched healthy controls did not differ from
those of the IBS patients and were significantly lower than
those of the patients with organic diarrhea (P  0.002,
Mann–Whitney test). Age-matched control patients with
Crohn disease had FC values higher than both IBS pa-
tients (P 0.0001) and those with organic diarrhea (P 
0.015, Mann–Whitney test).
All of the consecutive adult patients with chronic
diarrhea suffering from Crohn disease had high FC con-
Table 1. Number and percentage of pediatric and adult
patients included in the study and final diagnoses of the
individuals considered as controls.
No. of cases (%)
Children 50
IBS 15 (30%)
Patients with organic diarrhea 35 (70%)
Cow’s milk intolerance 15 (30%)
Celiac disease 13 (26%)
Multiple food intolerances 5 (10%)
Intestinal giardiasis 2 (4%)
Adults 70
IBS 40 (57%)
Patients with organic diarrhea 30 (43%)
Celiac disease 10 (14%)
Multiple food intolerances 2 (3%)
Colorectal cancer/adenomatous polyps 3 (4%)
Microscopic colitis 2 (3%)
Diverticulosis/diverticulitis 4 (6%)
Crohn disease 9 (13%)
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centrations (median, 320 g/g; range, 180–400 g/g),
and FC concentrations correlated significantly with the
Crohn Disease Activity Index (r  0.54; P 0.01). The
ROC curve plotted from the data of the consecutive
patients with final diagnoses of IBS or Crohn disease
showed that the calprotectin value with the highest diag-
nostic accuracy was 170 g/g: it was 100% sensitive and
95% specific in the diagnosis of Crohn disease. Further-
more, values above the cutoff limit of 50 g/g were
recorded in 5 of the 10 patients suffering from celiac
disease, in 2 of the 4 patients with diverticulosis/diver-
ticulitis, in both of the patients with microscopic colitis, in
1 of the 3 patients with colorectal cancer or adenomatous
polyps, and in neither of the 2 patients suffering from
multiple food intolerances.
Regarding the 40 adult patients with a final diagnosis
of IBS, we found FC values above the cutoff limit of 50
g/g in 8 cases. All of these patients had been previously
diagnosed as suffering from other diseases: liver cirrhosis
related to hepatitis C infection (three cases), ischemic
coronary disease (two cases), chronic bronchitis (two
cases), and chronic renal insufficiency (one case). Three of
the eight were taking aspirin, and one was taking NSAIDs
at the time of the study. Both the frequency of liver
cirrhosis (three of eight false-positive cases) and the use of
aspirin or NSAIDs (four of eight false-positive cases) were
significantly associated with false-positive calprotectin
results (P  0.026 and P 0.023, respectively, Fisher exact
test).
In our group of consecutive patients with chronic
diarrhea, 1 of the 9 (11%) patients with Crohn disease, 6 of
the 21 (29%) with other organic diseases, and 30 of the 40
(75%) with IBS fulfilled the Rome criteria for IBS diagno-
sis. Furthermore, in the diagnosis of “organic causes of
diarrhea”, C-reactive protein (upper limit of the reference
interval, 1 mg/L) and erythrocyte sedimentation rate
(upper limit of the reference interval, 12 mm/h) pro-
duced sensitivities of 40% and 66% and specificities of
90% and 63%, respectively.
In children with chronic diarrhea attributable to or-
ganic causes, FC concentrations above the cutoff of 50
g/g were found in 7 of the 13 patients with celiac
disease, 13 of the 15 patients with cow’s milk intolerance,
4 of the 5 patients with multiple food intolerances, but in
neither of the 2 patients with intestinal giardiasis infec-
tion. Ten of the patients with a final diagnosis of cow’s
milk intolerance or multiple food intolerances underwent
gastroscopy and/or sigmoidoscopy because they had
positive occult blood in the stool. In all of these patients,
duodenal or colon histology showed intense inflamma-
tory infiltration of the mucosa by polymorphonuclear
leukocytes (mainly eosinophils) and plasma cells. Only
one of the children with a final diagnosis of IBS had an FC
concentration above the cutoff limit of 50 g/g. She was
a patient with concomitant autoimmune hepatitis and
also underwent colonoscopy and small bowel x-ray ex-
amination for a suspected associated IBD, but these ex-
aminations and histology of the colon and ileum were
negative.
Children with organic diarrhea had significantly
higher FC values than those with IBS (P  0.04, Mann–
Whitney test). The values of the healthy controls did not
differ from those of the IBS patients and were significantly
lower than in the patients with organic diarrhea (P 
0.005, Mann–Whitney test). Pediatric controls suffering
from Crohn disease had FC values higher than both the
IBS patients (P 0.0001, Mann–Whitney test) and the
patients with organic diarrhea (P  0.01, Mann–Whitney
test). However, the correlation between FC concentration
and the Lloyd–Still activity score was not significant (r 
0.26; P  0.2).
A cross-tabulation of the calprotectin results obtained
in pediatric and adult patients, according to the final
diagnoses, is shown in Table 3, and Table 4 summarizes
the sensitivity, specificity, and positive and negative pre-
dictive values of the FC assay in distinguishing between
organic causes of diarrhea and IBS calculated in the study
Table 2. Median values and range of FC (expressed as
g/g of stool) in patients with IBS, patients with chronic
diarrhea from organic causes, and in the control groups,
according to age.
IBS
Diarrhea from
organic causes
Crohn disease
controls
Age-matched
healthy controls
Adults
n 40 30 10 10
Median 35 77.5 320 20
Range 10–210a,b 15–400a,c,d 155–450b,d 10–40c
Children
n 15 35 8 10
Median 20 45 260 15
Range 10–130e,f 20–200e,g,h 160–350f,h 10–40g
a–d Mann-Whitney test on results in adults: aIBS vs diarrhea from organic
causes, P  0.03; bIBS vs Crohn disease controls, P 0.0001; cdiarrhea from
organic causes vs age-matched healthy controls, P  0.002; ddiarrhea from
organic causes vs Crohn disease controls, P  0.015.
e–h Mann-Whitney test on results in children: eIBS vs diarrhea from organic
causes, P  0.04; fIBS vs Crohn disease controls, P 0.0001; gdiarrhea from
organic causes vs age-matched healthy controls, P  0.005; hdiarrhea from
organic causes vs Crohn disease controls, P  0.01.
Table 3. Cross-tabulation of the calprotectin results in
adult and pediatric patients with chronic diarrhea,
according to the final diagnoses.
IBS, n Organic diseases, n Total, n
Adults
Positive tests 8 19 27
Negative tests 32 11 43
Total 40 30 70
Children
Positive tests 1 24 25
Negative tests 14 11 25
Total 15 35 50
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population according to two cutoff limits indicated by the
manufacturer: 50 and 100 g/g of stool. The higher cutoff
(100 g/g) showed a higher positive predictive value but
a lower negative predictive value and sensitivity than the
lower cutoff value (50 g/g). In general, the assay was
more accurate in children than in adult patients.
Discussion
IBS has been reported to affect 6–20% of the general
population (9 ), and it is probably the most frequent cause
of chronic diarrhea in adults. Although simple clinical
criteria based on medical history and physical examina-
tion are suggested for a positive diagnosis of IBS, a
definitive diagnosis is still reached by excluding other
diseases, thus following a more or less aggressive inves-
tigation plan (3, 9). To limit the numerous and cumber-
some investigations, several noninvasive tests on blood or
stool samples have been proposed (17–20). Recently, FC
has been shown useful in identifying patients with
chronic diarrhea from IBD (4, 7), but almost all of the
studies published were performed in prediagnosed
groups of patients (21–24) or in patients in whom the
major clinical problem was to distinguish between Crohn
disease (or colon inflammation) and IBS (4, 7). Conse-
quently, these studies did not consider the wide spectrum
of other organic causes of chronic diarrhea that must be
distinguished from IBS. Furthermore, there are no pro-
spective data on the calprotectin assay in consecutive
children with chronic diarrhea.
Our data were collected according to a prospective
study design, and the percentage of patients initially
included and then excluded as lost during the follow-up
was 5% (6 of 126 patients). The data obtained fully
confirmed that the FC assay in adults can distinguish
between IBD and IBS (4, 7). In fact, in the consecutive
patients enrolled, we found that all individuals with a
final diagnosis of Crohn disease had FC values higher
than the highest cutoff chosen (100 g/g). However, it
must be emphasized that we studied a small control
group of individuals with IBD; consequently, these data
should not be overstated. FC values in the general group
of patients with organic causes of chronic diarrhea were
lower than in the patients with Crohn disease, and in the
diagnosis of organic diarrhea, the assay had 64% sensitiv-
ity and 80% specificity. This specificity is very close to
other previously reported values (4, 8), but we also high-
lighted two factors associated with the frequency of
false-positive results: the use of aspirin or NSAIDs and
the presence of concomitant liver cirrhosis. The associa-
tion between NSAID use and high fecal calprotectin
concentrations has been reported previously (25–27), and
although another study has shown conflicting data (4 ),
we suggest that NSAID use should be discontinued some
weeks before FC is assayed to assure higher specificity.
The evidence that patients with liver cirrhosis can have
false-positive calprotectin values is in agreement with the
report of frequent mucosa abnormalities in the colons
of patients with portal hypertension (28 ). Furthermore,
false-positive FC results have been reported to be attrib-
utable to day-to-day biological variations in calprotectin
excretion (29 )
The FC sensitivity in our series of adult patients was
lower (64%) than that reported previously. This is logical
because in the other studies, patients with a strong
suspicion of IBD were selected (4, 7), but it merits com-
ment if we consider the 89% sensitivity reported by Tibble
et al. (8 ) in a study that had a design similar to ours. In the
present study, we found a high frequency of negative
calprotectin results for patients with celiac disease, and as
these diagnoses represented approximately one-third of
the causes of “organic diarrhea”, this led to a low FC
sensitivity. Low FC sensitivity in patients with celiac
disease has not been reported previously, but it is consis-
tent with the typical intestinal histology of celiac disease,
characterized by a prevalently lymphocyte infiltration of
the mucosa, with few neutrophils (30 ). We must under-
line that the low sensitivity in our study may be attribut-
able to a selection bias because our hospital is a tertiary
care center for food intolerance (31, 32), and most of the
patients we enrolled could have been preselected by their
physicians. However, the frequency of celiac disease in
the general population is known to be on the increase in
both Europe and the US (33 ); consequently, an increase in
Table 4. Sensitivity, specificity, and positive and negative predictive values (and their 95% confidence intervals) for the FC
assay in the diagnosis of chronic diarrhea attributable to organic causes.a
Sensitivity, % Specificity, %
Positive predictive
value, %
Negative predictive
value, %
Cutoff of 50 g/g
All cases (n  120) 66 (55–77) 84 (77–91) 83 (76–90) 68 (58–78)
Adults (n  70) 64 (50–78) 80 (69–91) 70 (57–83) 74 (62–86)
Children (n  50) 70 (55–85) 93 (86–100) 96 (90–100) 56 (37–75)
Cutoff of 100 g/g
All cases (n  120) 46 (33–59) 93 (88–100) 90 (84–96) 59 (47–71)
Adults (n  70) 44 (26–62) 93 (87–99) 81 (71–91) 69 (53–82)
Children (n  50) 52 (32–72) 93 (86–100) 94 (87–100) 44 (23–65)
a Consecutive patients with chronic diarrhea were studied. The analysis was performed with two different cutoff limits: 50 and 100 g/g of stool.
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the “weighting” of celiac disease among the causes of
chronic diarrhea should be considered.
Regarding the range of FC values in our study in
patients with diarrhea from organic causes and in healthy
adult controls, it is interesting to note that they are
comparable to the values found in a population with
colorectal neoplasia and in the corresponding healthy
controls in another study performed with the same labo-
ratory method (34 ).
Recently, FC has been reported in groups of infants
with infantile colic and in children suffering from recur-
rent abdominal pain (35 ), and data from children highly
suspected to be suffering from IBD have been published
(36 ). However, no previous data on the usefulness of FC
in consecutive children with chronic diarrhea have been
published to date. We found that the calprotectin assay
had a higher sensitivity and specificity in children than in
adult patients. In fact, it would seem that false-positive
results are very rare in children, probably because of the
lower frequency of associated disease and the less-fre-
quent use of drugs that could damage the intestinal
mucosa. As in adult patients, the sensitivity of the calpro-
tectin assay in children was limited by false-negative
results in patients with celiac disease. Regarding the high
positive predictive value of FC that we obtained for the
pediatric patients (96%), we must emphasize that this is
also linked to the high prevalence of organic diseases
(70%) in our study group. It is possible that performing
the FC assay other than in a Gastroenterology Unit
situation could give a lower positive predictive value.
However, it is interesting to note that children with
chronic diarrhea attributable to cow’s milk allergy or
multiple food allergies had high calprotectin values in an
increased percentage of cases (17 of 20). Because food
allergy is one of the main causes of diarrhea in infants and
children and it has been reported that cow’s milk allergy
affects up to 8% of the pediatric population (37 ), it is
relevant that the FC assay was also a reliable marker for
organic causes of diarrhea in these patients. The high
sensitivity of FC in the set of food-intolerant patients is an
important finding because it is known that skin prick tests
and IgE antibodies do not detect allergies in most patients
with cow’s milk allergy (38, 39). Additional studies per-
formed on larger groups of patients with suspected food
allergies will be necessary to confirm the possible useful-
ness of FC in the laboratory work-up of this disease.
In conclusion, our study confirmed that the FC assay
identifies IBD in both children and adult patients. How-
ever, when used in consecutive adult patients with
chronic diarrhea, it can fail to identify some organic
causes, such as celiac disease, and can give false-positive
results attributable to concomitant extraintestinal diseases
or drug use. In pediatric patients, the calprotectin assay
had better sensitivity and specificity than in adult patients
in identifying organic causes of chronic diarrhea. Al-
though the negative predictive value of FC in children
(56%) in the present study does not permit this assay to be
considered as a screening test to exclude organic causes of
diarrhea, its high positive predictive value encourages its
use in the evaluation of children with chronic diarrhea.
We are grateful to Carole Greenall for reviewing the
English of this manuscript.
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